Skip to content
Middletown Life
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Wuxi Biologics
WuXi Biologics’ MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
July 9, 2026
WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year
July 8, 2026
WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy
June 30, 2026
WuXi Biologics’ 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
June 24, 2026
WuXi Biologics’ Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
June 18, 2026
WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards
June 8, 2026
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
June 4, 2026
WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year
June 2, 2026
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
May 27, 2026
WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
May 12, 2026
1
2
3
Next Page
→